Meda, Apotex Come To Terms In Astelin, Optivar Suits

Law360, New York (April 21, 2008, 12:00 AM EDT) -- Swedish pharmaceutical company Meda AB has settled the litigation it brought against Canadian generics maker Apotex Inc. to protect the markets for Meda's conjunctivitis treatment Optivar and its rhinitis treatment Astelin, which together brought in more than $200 million in U.S. sales in 2007.

Meda said Monday that the settlement arrangement would allow Apotex to launch a generic version of the nasal spray Astelin on March 1, 2010, provided that Apotex hands over 32.5% of its profits on the generic spray to Meda until Feb. 1,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.